Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.